The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody
Abstract
Antibodies block Ebola virus entry: The recent Ebola virus outbreak in West Africa illustrates the need for both an effective vaccine and therapies to treat infected individuals. Corti et al. isolated two monoclonal antibodies from a survivor of the 1995 Kikwit outbreak and demonstrated their therapeutic efficacy in Ebola virus–infected macaques. In fact, one antibody protected macaques when it was given up to 5 days after infection. Misasi et al. solved the crystal structures of fragments of the two antibodies bound to the Ebola virus glycoprotein (GP), which mediates viral cell entry. The two antibodies targeted different regions of GP, but in both cases blocked steps required for viral entry. Science , this issue pp. 1339 & 1343
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections
WHO Ebola Response Team (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411100 · Cited by 1,674
Tiller, T., Meffre, E., Yurasov, S., Tsuiji, M., Nussenzweig, M. C., & Wardemann, H. (2008) · Journal of Immunological Methods · doi:10.1016/j.jim.2007.09.017 · Cited by 1,107
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J. B., Fausther-Bovendo, H., Wei, H., Aviles, J., Hiatt, E., et al. (2014) · Nature · doi:10.1038/nature13777 · Cited by 987
Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor
Lee, J. E., Fusco, M. L., Hessell, A. J., Oswald, W. B., Burton, D. R., & Saphire, E. O. (2008) · Nature · doi:10.1038/nature07082 · Cited by 736
Traggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo, M. R., Murphy, B. R., Rappuoli, R., & Lanzavecchia, A. (2004) · Nature Medicine · doi:10.1038/nm1080 · Cited by 697
Self-citationSmall molecule inhibitors reveal Niemann–Pick C1 is essential for Ebola virus infection
Côté, M., Misasi, J., Ren, T., Bruchez, A., Lee, K., Filone, C. M., Hensley, L., Li, Q., Ory, D., Chandran, K., et al. (2011) · Nature · doi:10.1038/nature10380 · Cited by 686
Self-citationBarouch, D. H., Whitney, J. B., Moldt, B., Klein, F., Oliveira, T. Y., Liu, J., Stephenson, K. E., Chang, H.-W., Shekhar, K., Gupta, S., et al. (2013) · Nature · doi:10.1038/nature12744 · Cited by 644
Ebola haemorrhagic fever in Zaire
Otatume, S. (1996) · Journal of African Studies · doi:10.11619/africa1964.1996.49_95 · Cited by 474
Epitopes Involved in Antibody-Mediated Protection from Ebola Virus
Wilson, J. A., Hevey, M., Bakken, R., Guest, S., Bray, M., Schmaljohn, A. L., & Hart, M. K. (2000) · Science · doi:10.1126/science.287.5458.1664 · Cited by 459
Olinger, G. G., Pettitt, J., Kim, D., Working, C., Bohorov, O., Bratcher, B., Hiatt, E., Hume, S. D., Johnson, A. K., Morton, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213709109 · Cited by 366
Cited by
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Self-citationStructural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · doi:10.1101/2020.04.07.023903 · Cited by 1,752
Self-citationA Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Mulangu, S., Dodd, L. E., Davey, R. T., Tshiani Mbaya, O., Proschan, M., Mukadi, D., Lusakibanza Manzo, M., Nzolo, D., Tshomba Oloma, A., Ibanda, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910993 · Cited by 1,605
Self-citationCao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.025 · Cited by 1,188
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286
Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.-T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020) · Science · doi:10.1126/science.abc7520 · Cited by 1,230
“Furthermore, nAbs prevent death from the emerging Ebola virus in macaques, even when given relatively late in infection, and thus have been proposed for use in humans in outbreaks (2, 3).”
BackgroundStudies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Hansen, J., Baum, A., Pascal, K. E., Russo, V., Giordano, S., Wloga, E., Fulton, B. O., Yan, Y., Koon, K., Patel, K., et al. (2020) · Science · doi:10.1126/science.abd0827 · Cited by 1,210
Jacob, S. T., Crozier, I., Fischer, W. A., Hewlett, A., Kraft, C. S., Vega, M.-A. D. L., Soka, M. J., Wahl, V., Griffiths, A., Bollinger, L., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0147-3 · Cited by 664
The role of IgG Fc receptors in antibody-dependent enhancement
Bournazos, S., Gupta, A., & Ravetch, J. V. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00410-0 · Cited by 617
Efficient evolution of human antibodies from general protein language models
Hie, B. L., Shanker, V. R., Xu, D., Bruun, T. U. J., Weidenbacher, P. A., Tang, S., Wu, W., Pak, J. E., & Kim, P. S. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-01763-2 · Cited by 449
Malvy, D., McElroy, A. K., de Clerck, H., Günther, S., & van Griensven, J. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33132-5 · Cited by 419
Antibodies to combat viral infections: development strategies and progress
Pantaleo, G., Correia, B., Fenwick, C., Joo, V. S., & Perez, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00495-3 · Cited by 279
Self-citationPassive immunotherapy of viral infections: 'super-antibodies' enter the fray
Walker, L. M., & Burton, D. R. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.148 · Cited by 268
Nonhuman primate models of human viral infections
Estes, J. D., Wong, S. W., & Brenchley, J. M. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0005-7 · Cited by 255
A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
Alsoussi, W. B., Turner, J. S., Case, J. B., Zhao, H., Schmitz, A. J., Zhou, J. Q., Chen, R. E., Lei, T., Rizk, A. A., McIntire, K. M., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000583 · Cited by 181
Saphire, E. O., Schendel, S. L., Fusco, M. L., Gangavarapu, K., Gunn, B. M., Wec, A. Z., Halfmann, P. J., Brannan, J. M., Herbert, A. S., Qiu, X., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.033 · Cited by 212
Hastie, K. M., Salie, Z. L., Ke, Z., Halfmann, P. J., DeWald, L. E., McArdle, S., Grinyó, A., Davidson, E., Schendel, S. L., Hariharan, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56452-2 · Cited by 9
Metadata
- Authors
- Corti, D., Misasi, J., Mulangu, S., Stanley, D. A., Kanekiyo, M., Wollen, S., Ploquin, A., Doria-Rose, N. A., Staupe, R. P., Bailey, M., Shi, W., Choe, M., Marcus, H., Thompson, E. A., Cagigi, A., Silacci, C., Fernandez-Rodriguez, B., Perez, L., Sallusto, F., Vanzetta, F., Agatic, G., Cameroni, E., Kisalu, N., Gordon, I., Ledgerwood, J. E., Mascola, J. R., Graham, B. S., Muyembe-Tamfun, J.-J., Trefry, J. C., Lanzavecchia, A., & Sullivan, N. J.
- Venue
- Science
- Published
- 2016-03-18
- Volume
- 351
- Issue
- 6279
- Pages
- 1339-1342
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2288202420
- Cited by
- 408
- References
- 22
- FWCI
- 40.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.